AMGN Amgen
- 334.850
- +0.550+0.16%
- 335.000
- +0.150+0.04%
Amgen News
Amgen Inc.'s (NASDAQ:AMGN) Intrinsic Value Is Potentially 59% Above Its Share Price
Unpacking the Latest Options Trading Trends in Amgen
Amgen (AMGN) Stock Moves -0.39%: What You Should Know
Express News | The dividends of public funds have exceeded 100 billion yuan since the beginning of this year.
Here's What To Do Next After the Big Stock Market Slide
Market Whales and Their Recent Bets on AMGN Options
IBM, Amgen Share Gains Lead Dow's Nearly 175-Point Climb
Amgen Inc. Reaches All-time High at $339.19, Marking a Significant Milestone
The stock price of Nolit was hit hard after the new weight-loss drug Viking (VKTX.US), the "new star of weight-loss drugs", entered the late stage of research and development.
As Viking weight-loss drug enters the late stage of clinical trials, the stock prices of Eli Lilly and Co, and Novo Nordisk A/S have declined.
Viking Sends Lilly, Novo Lower as Obesity Drug Enters Late-stage Program
What Lies in Store for Healthcare ETFs in Q2 Earnings?
Amgen, Garmin Among Relative Market Leaders Poised to Outperform in Coming Months: BTIG
Investors in Amgen (NASDAQ:AMGN) Have Seen Splendid Returns of 122% Over the Past Five Years
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $360
TD Cowen analyst Yaron Werber maintains $Amgen(AMGN.US)$ with a buy rating, and maintains the target price at $360.According to TipRanks data, the analyst has a success rate of 61.7% and a total
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344
Piper Sandler analyst Christopher Raymond maintains $Amgen(AMGN.US)$ with a buy rating, and maintains the target price at $344.According to TipRanks data, the analyst has a success rate of 52.3% and
Beat the Market Like Zacks: Karooooo, UnitedHealth, Amgen in Focus
The trend of weight loss drug sector in US stock market is diverging. Novo Nordisk (NVO.US) and Eli Lilly and Co (LLY.US) face challenges to their duopoly.
As more and more pharmaceutical companies enter the lucrative weight loss drug market to get a share of the pie, the increasing competition is making investors worried about the duopoly position of Novo Nordisk and Eli Lilly and Co in this market.
Here Are Big Pharma's Leading Blockbuster Makers
Express News | Amgen Inc - Are Currently Assessing Global It Outage Impact and Are Working to Recover Impacted Systems as Quickly as Possible.
Jefferies Adjusts Price Target on Amgen to $380 From $375
Analysis
Price Target
No Data
